SOURCE: CLX Investment Company, Inc.

October 30, 2007 09:28 ET

CLX Investment Company Announces Management Transition With Appointment of Vera Leonard as CEO

MURRIETA, CA--(Marketwire - October 30, 2007) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced a management transition whereby consultant CEO Steven R. Peacock will step down from that position as of November 1, 2007, and Zonda chief executive officer Vera Leonard will be appointed to the position of president and chief executive officer of CLX.

Ms. Leonard possesses considerable successful experience in leadership positions with major medical manufacturing and distribution companies and has served as CEO of Zonda, Inc. since August of 2007.

With CLX's recent acquisition of a majority percentage of Zonda and the planned acquisition of the remaining 49% of its issued and outstanding shares, Ms. Leonard is considered to be the ideal person to lead CLX with Zonda operating as a subsidiary.

"Vera Leonard is uniquely qualified to lead CLX now that the medical diagnostic testing space has been positioned as the focus of the company's operations," stated Mr. Peacock. "CLX's Board of Directors has appointed her to the president/CEO position effective November 1st, and I am pleased to be stepping aside so that Vera can take the reins of the company and implement her vision of how CLX should be developed to deliver value to the company's shareholders.

"In her role as CEO of Zonda, Vera has conducted a thorough evaluation of the company's current operations and now has the ability to speak authoritatively on all aspects of its business. We look forward to her leadership of the public company and hope that shareholders will continue to follow the progress of CLX and its majority owned subsidiary, Zonda, Inc., under Vera's guidance," Mr. Peacock added.

Zonda's tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms. The Zonda medical diagnostic tests are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets.

Zonda's intellectual property position in enzymatic detection technology will give the company a unique position in the clinical diagnostic market where there is increasing need for simple, reliable, and cost-effective rapid point of care diagnostic tests. The company's first medical test for Chlamydia is currently sold throughout Europe under the HandiLab brand, and a U.S. launch is being planned. Zonda believes it will compete successfully with all current technologies, including the "gold standard" nucleic acid amplification testing (NAAT) technology, while offering several enhanced features.

More information regarding Zonda can be found on its official website, www.zondaincusa.com.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    951-677-8073
    Email Contact